KEGG   DRUG: Benralizumab
Entry
D09874                      Drug                                   
Name
Benralizumab (USAN/INN);
Benralizumab (genetical recombination) (JAN);
Fasenra (TN)
Product
FASENRA (AstraZeneca Pharmaceuticals LP)
Formula
C6492H10060N1724O2028S42
Exact mass
145964.5332
Mol weight
146054.48
Sequence
(Heavy chain)
EVQLVQSGAE VKKPGASVKV SCKASGYTFT SYVIHWVRQR PGQGLAWMGY INPYNDGTKY
NERFKGKVTI TSDRSTSTVY MELSSLRSED TAVYLCGREG IRYYGLLGDY WGQGTLVTVS
SASTKGPSVF PLAPSSKSTS GGTAALGCLV KDYFPEPVTV SWNSGALTSG VHTFPAVLQS
SGLYSLSSVV TVPSSSLGTQ TYICNVNHKP SNTKVDKKVE PKSCDKTHTC PPCPAPELLG
GPSVFLFPPK  PKDTLMISRT  PEVTCVVVDV  SHEDPEVKFN  WYVDGVEVHN  AKTKPREEQY
300 NSTYRVVSVL  TVLHQDWLNG  KEYKCKVSNK  ALPAPIEKTI  SKAKGQPREP
QVYTLPPSRD  ELTKNQVSLT  CLVKGFYPSD  IAVEWESNGQ  PENNYKTTPP
VLDSDGSFFL  YSKLTVDKSR  WQQGNVFSCS  VMHEALHNHY  TQKSLSLSPG  K
(Light chain)
DIQMTQSPSS LSASVGDRVT ITCGTSEDII NYLNWYQQKP GKAPKLLIYH TSRLQSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ GYTLPYTFGQ GTKVEIKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(Disulfide bridge: H22-H96, H148-H204, H265-H325, H371-H429, H230-H'230, H233-H'233, L23-L88, L134-L194, H224-L214)
  Type
Peptide
Class
Immunological agent
 DG02019  Interleukin inhibitor
Remark
Therapeutic category: 2290
ATC code: R03DX10
Product: D09874<JP/US>
Efficacy
Antiasthmatic, Anti-IL-5 receptor alpha antibody
  Disease
Asthma, eosinophilic phenotype [DS:H00079]
  Type
Monoclonal antibody
Target
IL5RA (CD125) [HSA:3568] [KO:K05067]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 R RESPIRATORY SYSTEM
  R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
   R03D OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
    R03DX Other systemic drugs for obstructive airway diseases
     R03DX10 Benralizumab
      D09874  Benralizumab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Respiratory Tract/Pulmonary Agents
  Respiratory Tract Agents, Other
   Immunomodulators
    Benralizumab
     D09874  Benralizumab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 2  Agents affecting individual organs
  22  Respiratory organ agents
   229  Miscellaneous
    2290  Miscellaneous
     D09874  Benralizumab (USAN/INN); Benralizumab (genetical recombination) (JAN)
Drug groups [BR:br08330]
 Immunological agent
  DG02019  Interleukin inhibitor
   D09874  Benralizumab
Drug classes [BR:br08332]
 Immunological agent
  DG02019  Interleukin inhibitor
   D09874  Benralizumab
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokine receptors
   Interleukin receptors
    IL5RA (CD125)
     D09874  Benralizumab (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D09874
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D09874
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D09874
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D09874
Other DBs
CAS: 1044511-01-4
PubChem: 124490602
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system